Select Topic:
Browse by Series:

Time Points in the Assessment of MRD

Panelists: Mark R. Litzow, MD, The Mayo Clinic; Jae Park, MD, Memorial Sloan Kettering Cancer Center; Bijal Shah, MD H. Lee Moffitt Cancer Center & Research Institute; Anthony Stein Gehr Family Center for Leukemia Research
Published: Friday, Feb 08, 2019



Transcript:

Mark R. Litzow, MD:
Anthony, when do you think we should be measuring MRD?

Anthony S. Stein, MD: I think it also depends which regimen you

SELECTED
LANGUAGE
Slider Left
Slider Right


Transcript:

Mark R. Litzow, MD:
Anthony, when do you think we should be measuring MRD?

Anthony S. Stein, MD: I think it also depends which regimen you
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Publication Bottom Border
Border Publication
x